Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2006

View Archived Issues

Trials reveal efficacy of Hylan G-F 20 in osteoarthritis

Various agents being tested for efficacy in Sjogren's syndrome

CoFactor begins phase III study in metastatic colorectal cancer

SBIR grant supports ArmaGen's development of AGT-140 for stroke

Oncolys Biopharma licenses Ed4T for HIV-1 from Yale University

Dosing under way in phase IIa nociceptive pain study of cannabinor

Eisai licenses SERMS to Radius Health

Nabi and Kedrion sign European agreement for Civacir

North American phase III study of Miraxion achieves target enrollment

Phase IIa study of oleoyl-estrone now dosing patients

Characterization of SPI-256 mutational escape pathways

deCODE files to begin phase I studies of DG-051 for heart attack prevention

Polyphenon E Ointment review extended

NDA submission for CIP-Tramadol ER

New KB-2115 formulation completes phase I study

Vertex enters into agreement for VX-950, begins initiative in HCV

New River files IND for NRP-409

NDA submission for Zensana Oral Spray

Epix files appeal over Vasovist approvable letters

RotaTeq approved in Europe

THRX-165724 tested in AML cell lines

HET-0016 shows efficacy in a rat brain tumor model

CHMP recommends Keppra monotherapy in epilepsy

European approval for Kaletra tablet

XY-8: Novel water-soluble camptothecin derivative active in preclinical tumor models

Novel norepinephrine and serotonin reuptake inhibitors imparted by Pfizer

Recent Abbott patent discloses novel vanilloid VR1 receptor antagonists

New antiinfective agents disclosed in recent patents

MS-560 demonstrates selectivity against matrix metalloproteinases involved in atherosclerosis

Promising preliminary results of phase I/II trial of ofatumumab in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...